Systematic Review and Meta-Analysis of Pulmonary Hypertension Specific Therapy for Exercise Capacity in Chronic Obstructive Pulmonary Disease

다국어 초록 (Multilingual Abstract)

Some patients with chronic obstructive pulmonary disease (COPD) have pulmonary hypertension (PH) that adversely affects survival. We performed a systematic review and meta-analysis to assess whether PH-specific therapies have an effect for stable COPD. Data sources were Medline, EMBASE, Cochrane Central Register of Controlled Trials, Korea med and references from relevant publications. Randomized prospective trials that compared PH specific therapy in COPD for more than 6 weeks with placebo were included. The outcomes were the exercise capacity and adverse events. Four randomized controlled trials involving 109 subjects were included in the analysis. Two trials involved bosentan, one sildenafil and one beraprost. The studies varied in duration of treatment from 3 to 18months. In a pooled analysis of four trials, exercise-capacity was not significantly improved with PH-specific treatment for COPD (risk ratio, -5.1; 95% CI, -13.0 to 2.8). COPD with overt PH significantly improved the exercise capacity (mean difference, 111.6; 95% CI,63.3 to 159.9) but COPD with PH unknown did not (mean difference, 26.6; 95% CI, -24.3to 77.5). There was no significant difference in hypoxemia (mean difference, 2.6; 95% CI,-3.7 to 8.8). PH specific treatments have a significant effect in improving exercise capacity in COPD with overt PH.

참고문헌 (Reference)

1 이상도, "만성폐쇄성폐질환 환자에서 Beraprost sodium의 효과에 대한 연구: 이중 맹검 무작위 임상시험" 대한결핵및호흡기학회 57 (57): 320-328, 2004

2 Kessler R, "“Natural history” of pulmonary hypertension in a series of 131 patients with chronic obstructive lung disease" 164 : 219-224, 2001

3 Barbera JA, "Worsening of pulmonary gas exchange with nitric oxide inhalation in chronic obstructive pulmonary disease" 347 : 436-440, 1996

4 Poor HD, "World Health Organization Group III pulmonary hypertension" 55 : 119-127, 2012

5 Park JS, "Udenafil improves exercise capacity in patients with chronic obstructive pulmonary disease: a prospective study" 9 : 499-504, 2012

6 Chin KM, "The right ventricle in pulmonary hypertension" 16 : 13-18, 2005

7 Rietema H, "Sildenafil treatment in COPD does not affect stroke volume or exercise capacity" 31 : 759-764, 2008

8 Rao RS, "Sildenafil improves six-minute walk distance in chronic obstructive pulmonary disease: a randomised, double-blind, placebo-controlled trial" 53 : 81-85, 2011

9 Barbera JA, "Pulmonary hypertension in chronic obstructive pulmonary disease" 21 : 892-905, 2003

10 Minai OA, "Pulmonary hypertension in COPD: epidemiology, significance, and management: pulmonary vascular disease: the global perspective" 137 : 39S-51S, 2010

11 Elwing J, "Pulmonary hypertension associated with COPD" 3 : 55-70, 2008

12 Humbert M, "Pulmonary arterial hypertension in France: results from a national registry" 173 : 1023-1030, 2006

13 Rubin LJ, "Primary pulmonary hypertension" 336 : 111-117, 1997

14 Sin DD, "Mortality in COPD: role of comorbidities" 28 : 1245-1257, 2006

15 Scharf SM, "Hemodynamic characterization of patients with severe emphysema" 166 : 314-322, 2002

16 Blanco I, "Hemodynamic and gas exchange effects of sildenafil in patients with chronic obstructive pulmonary disease and pulmonary hypertension" 181 : 270-278, 2010

17 Galie N, "Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT)" 30 : 2493-2537, 2009

18 Galie N, "Guidelines for the diagnosis and treatment of pulmonary hypertension" 34 : 1219-1263, 2009

19 Channick RN, "Effects of the dual endothelin- receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study" 358 : 1119-1123, 2001

20 Valerio G, "Effect of bosentan upon pulmonary hypertension in chronic obstructive pulmonary disease" 3 : 15-21, 2009

21 Higgins JP, "Cochrane handbook for systematic reviews of interventions" Wiley-Blackwell 2008

22 Santos S, "Characterization of pulmonary vascular remodelling in smokers and patients with mild COPD" 19 : 632-638, 2002

23 Yamakami T, "Arterial endothelin-1 level in pulmonary emphysema and interstitial lung disease: relation with pulmonary hypertension during exercise" 10 : 2055-2060, 1997

24 Stolz D, "A randomised, controlled trial of bosentan in severe COPD" 32 : 619-628, 2008